FindTrial
Sign In

Intralesional Diprospan injection for Infantile Hemangiomas on the lip: A Prospective Study

Intralesional Diprospan injection for Infantile Hemangiomas on the lip: A Prospective Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-17011276
Enrollment
Unknown
Registered
2017-05-01
Start date
2017-05-01
Completion date
Unknown
Last updated
2017-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infantile Hemangioma

Interventions

Treatment Group:Intralesional Diprospan injection

Sponsors

Shanghai Ninth People's Hospital, Shanghai Jiaotong University School Of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 1 Years

Inclusion criteria

Inclusion criteria: 1. Patients who were diagnosed with Infantile Hemangioma according to ISSVA diagnostic criteria; 2. Elevated Infantile Hemangioma on the lip, with a thickness greater than 3mm and diameter smaller than 3cm; 3. Aged under 1 year old; 4. Untreated lesion; 5. Willing to cooperate with treatment.

Exclusion criteria

Exclusion criteria: 1. Those who have received vaccination within a week prior to visit; 2. Those with immune deficiency and cannot be exposed to corticosteroids; 3. Patients with lesion ulceration history; 4. Patients who were unwilling to cooperate with treatment.

Design outcomes

Primary

MeasureTime frame
VAS;—

Countries

China

Contacts

Public ContactQiu Yajing

Shanghai Ninth People's Hospital, Shanghai Jiaotong University School Of Medicine

hedwig_qiu@live.cn+86 17701690005

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026